Natalie Staplin

PhD

MRC PHRU Senior Statistician

Natalie is a Senior Statistician within the Renal Studies Group at the Clinical Trials Service Unit & Epidemiological Studies Unit (CTSU). She is also a lecturer on the MSc in Global Health Sciences. She joined CTSU in 2012 after completing an undergraduate degree in Mathematics with Actuarial Science and a PhD in Statistics. Her current research interests are epidemiological analyses of patients with chronic kidney disease to identify risk factors associated with vascular events or progression to end-stage renal disease. She is particularly interested in competing risks methodology and the use of directed acyclic graphs in observational analyses.

Recent publications

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Journal article

LANDRAY M. et al, (2021), The Lancet
Tocilizumab in COVID-19 therapy: who benefits, and how? - Authors' reply.
Working paper

Horby P. et al, (2021), Lancet, 398
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19: A Meta-analysis.
Journal article

WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group None. et al, (2021), JAMA
Cardiac, renal, and metabolic effects of sodium-glucose co-transporter-2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium-glucose co-transporter-2 inhibitors
Journal article

HERRINGTON W. et al, (2021), European Journal of Heart Failure
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Journal article

RECOVERY Collaborative Group None. et al, (2021)